Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| VA Alcohol Research Center | Other Grant/Funding Number | VA Alcohol Research Center Grant | |
| P50AA012870 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| VA Connecticut Healthcare System | FED |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The proposed study is the first to explore the contribution of brain glutamate systems, a major target of ethanol in the brain, to the vulnerability to develop alcoholism. This study may lead to an enhanced understanding of the underlying neurobiological mechanism in high-risk individuals that may lead to the transition from moderate to excessive use of alcohol.
Males and females with a paternal family history of alcoholism have a high risk for developing alcoholism. These individuals have been shown to decrease dysphoric responses to alcohol self-administration that may promote the excessive use of alcohol. Ethanol has been shown to be an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor. We have recently shown that sober alcoholics have decreased dysphoric response to the NMDA antagonist, ketamine. We propose to test the hypothesis that this characteristic exists as a vulnerability factor in those individuals susceptible to develop alcoholism. Specifically, the objective is to determine whether individuals with a family history positive (FHP) for alcoholism will experience less dysphoric, anxiogenic, and psychotogenic effects to ketamine infusion when compared to family history negative (FHN) control subjects.
Male and female subjects, FHP (biological father and one other first degree relative) between the ages of 21-30, and matched controls (FHN) will complete 2 test days in a randomized balanced order under double-blind conditions. Test days will involve the 60-minute intravenous infusion of placebo and ketamine. Outcome measures include the Biphasic Alcohol Scale and visual analog scales for mood states. Secondary measures include visual analog scales for high, similarity to ethanol, the Sensation Scale (a validated measure of ethanol-like sensations) and aspects of craving for alcohol.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Family History Positive | Experimental | Subjects with a positive family history of alcoholism |
|
| Family History Negative | Experimental | Subjects with a negative family history of alcoholism |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketamine and Placebo | Drug | Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation | Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | Baseline |
| Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation | Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | 15 minutes |
| Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation | Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | 45 minutes |
| Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation | Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | 80 minutes |
| Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulation | Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | Baseline |
| Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulation |
Not provided
Not provided
Inclusion Criteria:
For Family History Positive (FHP) Subjects: Biological father and another first or second-degree biological relative with history of alcoholism
Exclusion Criteria:
For Family History Negative (FHN) Subjects: NO family history of alcoholism in any first or second-degree relatives (subjects must reliably report on three first-degree relatives)
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ismene L. Petrakis, MD | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| VA Connecticut Healthcare System | West Haven | Connecticut | 06516 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26475672 | Background | Yoon G, Pittman B, Limoncelli D, Krystal JH, Petrakis IL. Familial Alcoholism Risk and the Ratio of Stimulant to Sedative Effects of Ketamine. Biol Psychiatry. 2016 May 1;79(9):e69-e70. doi: 10.1016/j.biopsych.2015.09.006. Epub 2015 Sep 25. No abstract available. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Family History Positive | Subjects with a positive family history of alcoholism Ketamine and Placebo: Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes |
| FG001 | Family History Negative | Subjects with a negative family history of alcoholism Ketamine and Placebo: Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
All available data was utilized in the analysis using mixed models
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Family History Positive | Subjects with a positive family history of alcoholism Ketamine and Placebo: Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes |
| BG001 | Family History Negative |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation | Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | All available data was utilized in the analysis using mixed models | Posted | Mean | Standard Deviation | units on a scale | Baseline |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Family History Positive | Subjects with a positive family history of alcoholism Ketamine: Ketamine: 0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute for 60 minutes, IV Placebo: Placebo: loading dose and an infusion for 60 minutes saline solution |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anxiety | Psychiatric disorders | Subjects stopped infusion felt very anxious |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Ismene Petrakis | Yale University | 203-932-5711 | 2244 | Ismene.petrakis@yale.edu |
Not provided
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D007649 | Ketamine |
| ID | Term |
|---|---|
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. |
| 15 minutes |
| Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulation | Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | 45 minutes |
| Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulation | Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | 80 minutes |
Subjects with a negative family history of alcoholism Ketamine and Placebo: Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Subjects with a negative family history of alcoholism Ketamine: Ketamine: 0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute for 60 minutes, IV Placebo: Placebo: loading dose and an infusion for 60 minutes saline solution |
|
|
| Primary | Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation | Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | All available data was utilized in the analysis using mixed models | Posted | Mean | Standard Deviation | units on a scale | 15 minutes |
|
|
|
| Primary | Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation | Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | All available data was utilized in the analysis using mixed models | Posted | Mean | Standard Deviation | units on a scale | 45 minutes |
|
|
|
| Primary | Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation | Self-reporting rating scale to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | All available data was utilized in the analysis using mixed models | Posted | Mean | Standard Deviation | units on a scale | 80 minutes |
|
|
|
| Primary | Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulation | Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | All available data was utilized in the analysis using mixed models | Posted | Mean | Standard Deviation | units on a scale | Baseline |
|
|
|
| Primary | Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulation | Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | All available data was utilized in the analysis using mixed models | Posted | Mean | Standard Deviation | units on a scale | 15 minutes |
|
|
|
| Primary | Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulation | Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | All available data was utilized in the analysis using mixed models | Posted | Mean | Standard Deviation | units on a scale | 45 minutes |
|
|
|
| Primary | Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulation | Self-reporting rating scale to measure the stimulation effects (0 not at all stimulated - 70 extremely stimulated) of alcohol effects. We used the BAES to measure alcohol-like effects in subjects that received ketamine infusions. | All available data was utilized in the analysis using mixed models | Posted | Mean | Standard Deviation | units on a scale | 80 minutes |
|
|
|
| 0 |
| 29 |
| 0 |
| 29 |
| EG001 | Family History Negative | Subjects with a negative family history of alcoholism Ketamine: Ketamine: 0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute for 60 minutes, IV Placebo: Placebo: loading dose and an infusion for 60 minutes saline solution | 0 | 70 | 2 | 70 |
| Vomiting | Gastrointestinal disorders | Subject vomited during infusion so infusion was stopped. |
|
Not provided
Not provided
Not provided
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| Placebo |
|
|
| Placebo |
|
|
| Placebo |
|
|
| Placebo |
|
|
| Placebo |
|
|
| Placebo |
|
|
| Placebo |
|
|